Resveratrol: Biologic and therapeutic implications

Journal of the CardioMetabolic Syndrome

Volumn 4, Issue 2, 2009, Pages 102-106

  Sadruddin, Sarfaraz ^a   Arora, Rohit ^a,b  

^a The Chicago Medical College   (United States)

^b Chicago Medical School NCVAMC 133 B   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ENDOTHELIN 1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; RESVERATROL; SIRTUIN 1; THROMBOXANE B2; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOGENESIS; ANTIARRHYTHMIC ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; CALORIC INTAKE; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; DRUG STRUCTURE; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEART ARRHYTHMIA; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; ISCHEMIC PRECONDITIONING; LIPID DIET; LIPID METABOLISM; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; BLOOD GLUCOSE; CALORIC RESTRICTION; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIETARY CARBOHYDRATES; DIETARY FATS; ENERGY INTAKE; HOMEOSTASIS; HUMANS; LIPID METABOLISM; METABOLIC SYNDROME X; MOLECULAR STRUCTURE; SIRTUINS; STILBENES;

EID: 65349091486     PISSN: 15594564     EISSN: 15594572     Source Type: Journal    
DOI: 10.1111/j.1559-4572.2008.00039.x     Document Type: Review

References (36)

1. Seimann EH, Creasy LL. Concentration of the phytoalexin resveratrol in wine. Am J Enol Vitic. 1992;43:49-52.
2. Lagouge M, Argmann C, Gerhart Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC1-alpha. Cell. 2006;127:1109-1122.
3. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health survival of mice on a high-calorie diet. Nature. 2006;444:337-342.
4. Jain P, Lahiri A. Metabolic syndrome: An evolving threat in the genesis of coronary artery disease. JCMS. 2007;2:190-197.
5. Park CE, Kim MJ, Lee JH, et al. Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp Mol Med. 2007;39(2):222-229.
6. Ector BJ, Magee JB, Hegwood CP, et al. Resveratrol concentration in muscadine berries, juice, pomace, purees, seeds, and wines. Am J Enol Vitic. 1996;7(1):57-62.
7. Walle T, Hsieh F, Delegge MH, et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32(12):1377-1382.
8. Chen CK, Pace-Asciak CR. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol. 1996;27:363-366.
9. Orallo F, Alvarez E, Camina M, et al. The possible implication of trans-resveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol Pharmacol. 2002;61:294-302.
10. Yang LC, Wang F, Liu M. A study of an endothelin antagonist from a Chinese anti-snake venom medicinal herb. J Cardiovasc Pharmacol. 1998;31:S249-S250.
11. Zou JG, Wang ZR, Huang YZ, et al. Effect of red wine and wine polyphenol resveratrol on endothelial function in hypercholesterolemic rabbits. Int J Mol Med. 2003;11:317-320.
12. Wallerath T, Deckert G, Ternes T, et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation. 2002;106(13):1652-1658.
13. Frankel EN, Waterhouse AL, Kinsella JE. Inhibition of human LDL oxidation by resveratrol. Lancet. 1993;341:1103-1104.
14. Belguendouz L, Fremont L, Linard A. Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem Pharmacol. 1997;53:1347-1355.
15. Goldberg DM, Hahn SE, Parkes JG. Beyond alcohol: Beverage consumption and cardiovascular mortality. Clin Chim Acta. 1995;237:155-187.
16. Carluccio MA, Siculella L, Ancora MA, et al. Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: Antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler Thromb Vasc Biol. 2003;23:622-629.
17. Ferrero ME, Bertelli AE, Fulgenzi A, et al. Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Am J Clin Nutr. 1998;68:1208-1214.
18. Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κB, activator protein-1, and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol. 2000;164:6509-6519.
19. Faxon DP, Fuster V, Libby P, et al. Atherosclerotic Vascular Disease Conference: WPiting Group III: pathophysiology. Circulation. 2004;109:2617-2625.
20. Haider U, Sorescu D, Griendling KK, et al. Resveratrol increases serine15-phosphorylated but transcriptionally impaired p53 and induces a reversible DNA replication block in serum-activated vascular smooth muscle cells. Mol Pharmacol. 2003;63(4):925-932.
21. Mnjoyan ZH, Fujise K. Profound negative regulatory effects by resveratrol on vascular smooth muscle cells: A role of p53-p21WAF1/CIP1 pathway. Biochem Biophys Res Commun. 2003;311(7):546-552.
22. Guevara NV, Kim HS, Antonova EI, et al. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat Med. 1999;5:335-339.
23. Das DK, Maulik N. Resveratrol in cardioprotection: A therapeutic promise of alternate medicine. Mol Interv. 2006;6:36-47.
24. Kimura Y, Okuda H, Arichi S. Effects of stilbenes on arachidonate metabolism in luekocytes. Biochim Biophys Acta. 1985;834:275-278.
25. Pace-asciak CR, Rounova O, Hahn S, et al. Wines and grape juices as modulators of platelet aggregation in healthy human subjects Clin. Chim Acta. 1996;246:163-182.
26. Wang Z, Huang Y, Zou J, et al. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int J Mol Med. 2002;9(1):77-79.
27. Kirk RI, Deitch JA, Wu JM, et al. Resveratrol decreases early signaling events in washed platelets but has little effect on platelet in whole blood. Blood Cells Mol Dis. 2000;26(2):144-150.
28. Schafer C, Ladilov Y, Inserte J, et al. Role of the reverse mode of the Na1/Ca2+ exchanger in reoxygenation-induced cardiomyocyte injury. Cardiovasc Res. 2001;51:241-250.
29. Hung LM, Chen JK, Lee RS, et al. Beneficial effects of astringinin, a resveratrol analogue, on the ischemia and reperfusion damage in rat heart. Free Radic Biol Med. 2001;30(8):877-883.
30. Hung LM, Chen JK, Huang SS, et al. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardio Res. 2000;47:549-555.
31. Dernek S, Ikizler M, Erkasap N, et al. Cardioprotection with resveratrol pretreatment: Improved beneficial effects over standard treatment in rat hearts after global ischemia. Scand Cardiovasc J. 2004;38(4):245-254.
32. Chen WP, Su MJ, Hung LM. In vitro electrophysiological mechanisms for antiarrhythmic efficacy of resveratrol, a red wine antioxidant. Eur J Pharmacol. 2007;554(2-3):196-204.
33. Picard F. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature. 2004;429:771-776.
34. Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature. 2006;444(7121):868-874.
35. Bordone L, Motta MC, Picard F, et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta-cells. PloS Biol. 2006;4(2):e31.
36. Moynihan KA, Grimm AA, Plueger MM, et al. Increased dosage of mammalian Sir2 in pancreatic cells enhances glucose-stimulated insulin secretion in mice. Cell Metab. 2005;2(2):105-117.